Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Gynaecology
  4. Gynaecology guidelines
  5. Back
  6. Guidelines A-Z (all Gynaecology guidelines)
  7. Progesterone use in early pregnancy (1097)
Important: please update your RDS app to version 4.7.3

Welcome to the March 2025 update from the RDS team

1.     RDS issues - resolutions

1.1 Stability issues - Tactuum implemented a fix on 24th March which we believe has finally addressed the stability issues experienced over recent weeks.  The issue seems to have been related to the new “Tool export” function making repeated calls for content when new toolkit nodes were opened in Umbraco. No outages have been reported since then, and no performance issues in the logs, so fingers crossed this is now resolved.

1.2 Toolkit URL redirects failing– these were restored manually for the antimicrobial calculators on the 13th March when the issue occurred, and by 15th March for the remainder. The root cause was traced to adding a new hostname for an app migrated from another health board and made live that day. This led to the content management system automatically creating internal duplicate redirects, reaching the maximum number of permitted redirects and most redirects therefore ceasing to function.

This issue should not happen again because:

  • All old apps are now fully migrated to RDS. The large number of migrations has contributed to the high number of automated redirects.
  • If there is any need to change hostnames in future, Tactuum will immediately check for duplicates.

1.3 Gentamicin calculators – Incidents have been reported incidents of people accessing the wrong gentamicin calculator for their health board.  This occurs when clinicians are searching for the gentamicin calculator via an online search engine - e.g. Google - rather than via the health board directed policy route. When accessed via an external search engine, the calculator results are not listed by health board, and the start page for the calculator does not make it clearly visible which health board calculator has been selected.

The Scottish Antimicrobial Prescribing Group has asked health boards to provide targeted communication and education to ensure that clinicians know how to access their health board antimicrobial calculators via the RDS, local Intranet or other local policy route. In terms of RDS amendments, it is not currently possible to change the internet search output, so the following changes are now in progress:

  • The health board name will now be displayed within the calculator and it will be made clear which boards are using the ‘Hartford’ (7mg/kg) higher dose calculator
  • Warning text will be added to the calculator to advise that more than one calculator is in use in NHS Scotland and that clinicians should ensure they access the correct one for their health board. A link to the Right Decision Service list of health board antimicrobial prescribing toolkits will be included with the warning text. Users can then access the correct calculator for their Board via the appropriate toolkit.

We would encourage all editors and users to use the Help and Support standard operating procedure and the Editors’ Teams channel to highlight issues, even if you think they may be temporary or already noted. This helps the RDS team to get a full picture of concerns and issues across the service.

 

2.     New RDS presentation – RDS supporting the patient journey

A new presentation illustrating how RDS supports all partners in the patient journey – multiple disciplines across secondary, primary, community and social care settings – as well as patients and carers through self-management and shared decision-making tools – is now available. You will find it in the Promotion and presentation resources for editors section of the Learning and support toolkit.

3.     User guides

A new user guide is now available in the Guidance and tips section of Resources for providers within the Learning and Support area, explaining how to embed content from Google Calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream and Jotforms into RDS pages. A webinar for editors on using this new functionality is scheduled for 1 May 3-4 pm (booking information below.)

A new checklist to support editors in making all the checks required before making a new toolkit live is now available at the foot of the “Request a new toolkit” standard operating procedure. Completing this checklist is not a mandatory part of the governance process, but we would encourage you to use it to make sure all the critical issues are covered at point of launch – including organisational tags, use of Alias URLs and editorial information.

4.Training sessions for RDS editors

Introductory webinars for RDS editors will take place on:

  • Tuesday 29th April 4-5 pm
  • Thursday 1st May 4-5 pm

Special webinar for RDS editors – 1 May 3-4 pm

This webinar will cover:

  1. a) Use of the new left hand navigation option for RDS toolkits.
  2. b) Integration into RDS pages of content from external sources, including Google Calendar, Google Maps and simple Jotforms calculators.

Running usage statistics reports using Google analytics

  • Wednesday 23rd April 2pm-3pm
  • Thursday 22nd May 2pm-3pm

To book a place on any of these webinars, please contact Olivia.graham@nhs.scot providing your name, role, organisation, title and date of the webinar you wish to attend.

5.New RDS toolkits

The following toolkits were launched during March 2025:

SIGN guideline - Prevention and remission of type 2 diabetes

Valproate – easy read version for people with learning disabilities (Scottish Government Medicines Division)

Obstetrics and gynaecology induction toolkit (NHS Lothian) – password-protected, in pilot stage.

Oral care for care home and care at home services (Public Health Scotland)

Postural care in care homes (NHS Lothian)

Quit Your Way Pregnancy Service (NHS GGC)

 

6.New RDS developments

Release of the redesign of RDS search and browse, archiving and version control functionality, and editing capability for shared content, is now provisionally scheduled for early June.

The Scottish Government Realistic Medicine Policy team is leading development of a national approach to implementation of Patient-Reported Outcome Measures (PROMs) as a key objective within the Value Based Health and Care Action Plan. The Right Decision Service has been commissioned to deliver an initial version of a platform for issuing PROMs questionnaires to patients, making the PROMs reports available from patient record systems, and providing an analytics dashboard to compare outcomes across services.  This work is now underway and we will keep you updated on progress.

The RDS team has supported Scottish Government Effective Prescribing and Therapeutics Division, in partnership with Northern Ireland and Republic of Ireland, in a successful bid for EU funding to test develop, implement and assess new integrated care pathways for polypharmacy, including pharmacogenomics. As part of this project, the RDS will be working with NHS Tayside to test extending the current polypharmacy RDS decision support in the Vision primary care electronic health record system to include pharmacogenomics decision support.

7. Implementation projects

We have just completed a series of three workshops consulting on proposed improvements to the Being a partner in my care: Realistic Medicine together app, following piloting on 10 sites in late 2024. This app has been commissioned by Scottish Government Realistic Medicine to support patients and citizens to become active partners in shared decision-making and encouraging personalised care based on outcomes that matter to the person. We are keen to gather more feedback on this app. Please forward any feedback to ann.wales3@nhs.scot

 

 

Progesterone use in early pregnancy (1097)

Objectives

To provide guidance for the provision of progesterone therapy to women in early pregnancy

Audience

Healthcare Workers in primary and secondary care involved in the care of women in early pregnancy within GG&C

Please report any inaccuracies or issues with this guideline using our online form

This guideline is based on the recently updated NICE guidance (1), whose recommendations are taken from a review of 7 randomised controlled trials including the PRISM and Promise trials. It relates to the use of progesterone in women at risk of miscarriage.

Summary:

  • No benefit of progesterone treatment was found for women with a threatened miscarriage who have no history of miscarriage.
  • Benefit of using vaginal progesterone was found in women who had a threatened miscarriage and a history of one or more miscarriages.
  • No benefit of progesterone treatment was found in women who had a history of recurrent miscarriage.
  • No harm or adverse effects were found in women treated with progesterone

  • Women with bleeding in early pregnancy and a past history of miscarriage should be offered progesterone therapy from confirmation scan until 12 weeks gestation (or until 16 weeks gestation after counselling – see patient information leaflet in Appendix 1)
  • An intrauterine pregnancy should be confirmed by scan before commencement of progesterone and this should confirm presence of an intrauterine sac +/- yolk sac
  • In women who have had progesterone given in previously successful pregnancies and request this treatment again, advice should be given that there is no proven benefit (unless there is current bleeding) but also no proven harm. Prescription can be made on an individual basis.
  • In women with a history of recurrent miscarriage (3 or more) who request treatment, advice should be given that there is no proven benefit (unless there is current bleeding) but also no proven harm. Prescription can be made on an individual basis.

  • The progesterone used should be a vaginal micronized preparation as below.
    • 1st line : Cyclogest 400mg, administered vaginally twice a day.
    • 2nd line Utrogestan 400mg, administered vaginally twice a day.
  • Treatment should be commenced before 9 weeks as no proven benefit beyond this gestation. Can be discussed on an individualised basis if patient requests (see Patient information leaflet, Appendix 1)
  • An initial prescription should be given at the Early Pregnancy Assessment Service (EPAS) after scan as above. The initial prescription will be for 2 weeks, which should then be continued by their GP until 12 weeks gestation (unless previous agreement to continue until 16 weeks)
  • 2 copies of the Patient information leaflet and consent form should be signed, with 1 copy filed in patient notes and 1 copy given to the patient (Appendix 1)

  • Hypersensitivity to progesterone, Sunflower oil, Soybean lecithin, Gelatin, Glycerol, Titanium dioxide (those allergic to peanuts may also be allergic to soya). Severe hepatic dysfunction, Undiagnosed vaginal bleeding, Mammary or genital tract carcinoma, Thrombophlebitis, Thromboembolic disorders, Cerebral haemorrhage, Porphyria.

  • If a miscarriage occurs in women taking progesterone therapy, this should be stopped for 4 days prior to active medical management.

Consent form for use of Micronised Vaginal Progesterone treatment in women with early pregnancy bleeding and previous miscarriage

Editorial Information

Last reviewed: 16/08/2023

Next review date: 31/07/2028

Author(s): Dr Lynne Thomson.

Version: 1

Co-Author(s): Dr Anusha D’Sa.

Approved By: Gynaecology Clinical Governance Group

Document Id: 1097